Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials
By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore. Read More
|
|
|
DIA 2010 – Innovation, Issues-Driven, Upbeat
Jul 19 | eCliniqua | The 46th Annual Meeting of the Drug Information Association (DIA) held last month in Washington, D.C. sported a decidedly optimistic tone. A whole host of sessions and exhibits highlighted strategic partnerships among multiple stakeholders, the growing role of payers and comparative effectiveness research, electronic health records, continued globalization, and of course, the latest technological solutions.
|
|
DIA Bits & Pieces
Jun 15 | Announcements and products from the Drug Information Association meeting in Washington, D.C., June 13-17.
|
|
A Social Approach to Patient Recruitment
Jun 7 | eCliniqua | Better use of Web 2.0 sites like Twitter, Facebook and PatientsLikeMe could be a boon for enrollment.
|
|
Dana-Farber Chooses Clinical Research Management System
May 20 | News Brief | Dana-Farber/Harvard Cancer Center has chosen OnCore as their integrated clinical research management system.
|
|
Quanticate Selects Oracle Argus Safety for Pharmacovigilance Database
May 17 | eCliniqua | Quanticate has selected Oracle Argus Safety as its safety database to offer comprehensive global adverse event management and reporting for its customers.
|
|
Covance Launches Translational Services
May 13 | News Brief | Covance has created a Discovery & Translational Services group, which will integrate its discovery services, antibody products and immunology services.
|
|
Reforms to Help Australia Maintain its Share of Global Trials
Apr 19 | eCliniqua | Australia is in the process of reforming itself to better accommodate the clinical trials industry amidst competition from emerging markets in Eastern Europe, Latin America, and Asia.
|
|
Pen-Based Site Visit Reporting Solutions
Feb 10 | Expert Commentary | The preferred workflow of most health care professionals continues to be pen-based, not keyboard-based. Several technologies have been developed recently that address this issue of EDC in a clinician-friendly manner with electronic pen-on-paper systems, including the Digital Pen and Tablet PC.
|
|
Study Finds ‘Operational Gap’ in Clinical Trial Portfolio Management
Feb 3 | eCliniqua | For most biopharmaceutical companies, the pressure to improve clinical trial portfolio management efficiency has arrived sooner than their operational readiness to meet the challenge. Corporate intolerance for budget variances above 5% of target is now commonplace. But widespread absence of project-level operational metrics has made it all but impossible to drive planned-to-actual spending into alignment.
|
|
Moonbay Sells Document Management Services Via Cloud Computing
Oct 20 | Moonbay Technology entered the field of regulatory document management and electronic submissions in June with an option affordable even to small biotechnology firms heretofore reliant primarily on homegrown, error-prone systems.
|
 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide
Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:
- Current practices in clinical trial logistics
- Comparing advances in clinical supply practices to other aspects of clinical trials
- Where current practices fall short of meeting the challenges
- Trends and evolving improvements that may change the way logistics are conducted
Listen Now
More Podcasts
Scientific Software Engineer
Boston MA
$70,000 to $95,000
Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET.
Apply at http://jobs.tessella.com
Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes. As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers. This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions. It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply
Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules. It is therefore suitable for use in a variety of markets including scientific research and clinical applications. As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team. The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market. This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company. Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial leadership, who wish to apply a fresh approach to existing markets. Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries. We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products. Click to Apply
|
|
|